What is Dogwood Therapeutics, Inc.'s (DWTX) StockRank?

MoatMap's StockRank for Dogwood Therapeutics, Inc. (DWTX) is 9/100, with a Strong Sell signal. This is a composite score combining Quality (34), Value (35), and Momentum (15) factor ranks across MoatMap's 20,000+ stock universe.

Does Dogwood Therapeutics, Inc. have an economic moat?

Dogwood Therapeutics, Inc. (DWTX) has a Quality factor score of 34/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Dogwood Therapeutics, Inc. a buy, hold, or sell?

MoatMap's current signal for Dogwood Therapeutics, Inc. (DWTX) is Strong Sell, based on a StockRank of 9/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Dogwood Therapeutics, Inc. in?

Dogwood Therapeutics, Inc. (DWTX) operates in the Healthcare sector, specifically the Biotechnology industry (United States).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

DWTX

STRONG SELL

Dogwood Therapeutics, Inc. · Healthcare · United States · $55M · Avg Vol: $136K/d

StockRank

Get insider-trade alerts

P/E (TTM)

1.2x

ROE

-34.7%

D/E

0.0x

Dividend %

—

COMPANY DESCRIPTION

Dogwood Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel antiviral therapies to treat chronic diseases, including fibromyalgia and long-COVID. The company's competitive position is anchored by its proprietary combination therapies targeting herpes simplex virus type 1 (HSV-1) as a potential driver of chronic illness. It operates as a niche clinical developer addressing high-barrier, underserved patient populations.

FINANCIAL SUMMARY (USD)

Year	2022	2023	2024	2025	CAGR	TTM
Revenue	0	0	0	0	—	—
EPS	-0.61	-0.16	-0.50	-7.13	—	1.14
Shares	33.6M	33.6M	33.6M	29.7M	-11.6%	33.6M
Debt	—	0	15.6M	0.2M	-99.0%	0.1M
Equity	7.3M	3.8M	64.3M	74.9M	117.0%	—
Op CF	-11.5M	-4.9M	-8.8M	-15.6M	—	-15.5M
Inv CF	—	0	3.8M	0	—	—
Fin CF	4.5M	1.2M	16.7M	7.3M	—	—

Loading 1Y...

PRICE (1Y)-17.5%

SMA 50SMA 200

$1.41

RSI (14)

45.7

52W High

$9.50

From 52W High

0.1%

SCORE BREAKDOWN

Quality

ROIC

-32.1%21.2

ROE

-34.7%23.4

GP/Assets

—N/A

Op. Margin

0.0%40.3

FCF/Assets

-19.1%17.6

Piotroski

321.8

Int. Cover

—N/A

D/E Ratio

0.00x96.3

Current Ratio

5.86x76.0

Value

P/E (TTM)

1.2x25.0

EV/EBITDA

-1.2x25.0

P/FCF

—N/A

P/B

0.6x93.9

P/S

—N/A

Div Yield

—N/A

Momentum

52W High %

15%1.4

RS 6M

-74%11.1

SMA 50/200

0.45x1.2

EPS Rev 4W

0.0%64.0

EPS Rev 12W

—N/A

EPS Improve

-659%0.8

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$55M

P/E (Forward)

-0.2x

Gross Margin

0.0%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of DWTX are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
DWTX	Dogwood Therapeutics, Inc.(you)	$55M	9	STRONG SELL
FLNA	Filana Therapeutics, Inc.	$58M	9	STRONG SELL
CNTX	Context Therapeutics Inc.	$53M	10	STRONG SELL
TIL	Instil Bio, Inc.	$50M	10	STRONG SELL
ATYR	aTyr Pharma, Inc.	$52M	4	STRONG SELL
KALA	KALA BIO, Inc.	$63M	4	STRONG SELL
GOSS	Gossamer Bio, Inc.	$77M	7	STRONG SELL
CING	Cingulate Inc.	$67M	13	STRONG SELL
HRTX	Heron Therapeutics, Inc.	$81M	8	STRONG SELL
4875.T	MediciNova, Inc.	$62M	15	STRONG SELL

Peer medians: ROE -21.2% · P/E 27.3x · Gross margin 44.5%

Dogwood Therapeutics, Inc. (DWTX) — Stock Score Summary

Dogwood Therapeutics, Inc. (DWTX) has a MoatMap StockRank of 9/100 based on Quality (34/100), Value (35/100), and Momentum (15/100) factor scores. The current signal is STRONG SELL.

Key Financial Metrics

Price	$1.41
Market Cap	$55M
P/E (TTM)	1.24
P/E (Forward)	-0.22
Price/Book	0.58
Return on Equity	-34.7%
Return on Invested Capital	-32.1%
Debt/Equity	0.18
Gross Margin	0.0%
Operating Margin	0.0%
Free Cash Flow	$-17M

Dogwood Therapeutics, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Dogwood Therapeutics, Inc.’s (DWTX) StockRank?: MoatMap’s StockRank for Dogwood Therapeutics, Inc. (DWTX) is 9/100, with a Strong Sell signal. It is a composite of Quality (34), Value (35), and Momentum (15) factor ranks across MoatMap’s 20,000+ stock universe.
Does Dogwood Therapeutics, Inc. have an economic moat?: Dogwood Therapeutics, Inc. (DWTX) has a Quality factor score of 34/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Dogwood Therapeutics, Inc. a buy, hold, or sell?: MoatMap’s current signal for Dogwood Therapeutics, Inc. (DWTX) is Strong Sell, based on a StockRank of 9/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Dogwood Therapeutics, Inc. in?: Dogwood Therapeutics, Inc. (DWTX) operates in the Healthcare sector, specifically the Biotechnology industry (United States).